Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Metrics to compare | SYBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYBXPeersSector | |
---|---|---|---|---|
P/E Ratio | 7.0x | −4.0x | −0.5x | |
PEG Ratio | 0.07 | 0.00 | 0.00 | |
Price/Book | 1.4x | 2.7x | 2.6x | |
Price / LTM Sales | - | 193.3x | 3.2x | |
Upside (Analyst Target) | −35.9% | 126.3% | 42.0% | |
Fair Value Upside | Unlock | 8.3% | 6.6% | Unlock |